Bristol Myers wins a megablockbuster bet with TYK2 FDA approval — and there's a big bonus for the label

John Carroll

Editor & Founder

Amber Tong

Bristol Myers Squibb made a megablockbuster bet on deucravacitinib, an in-house experimental TYK2 drug, in the leadup to the big Celgene buyout, keeping it while …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers wins a megablockbuster bet with TYK2 FDA approval — and there's a big bonus for the label

John Carroll

Editor & Founder

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Bris­tol My­ers wins a megablock­buster bet with TYK2 FDA ap­proval — and there's a big bonus for the la­bel

Editor & Founder

Sign up to read this article for free.

more like this

Bristol Myers wins a megablockbuster bet with TYK2 FDA approval — and there's a big bonus for the label